| Name | N-acetyltransferase 2 (arylamine N-acetyltransferase) |
| Description | This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second polymorphic arylamine N-acetyltransferase gene (NAT1), is located near this gene (NAT2). [provided by RefSeq, Sep 2019] |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nN‐acetyltransferase 2 (NAT2) is a polymorphic phase II xenobiotic‐metabolizing enzyme that catalyzes the acetylation of aromatic amines and hydrazine drugs. This enzyme plays a dual role by participating in both detoxification and bioactivation processes for environmental chemicals—such as those encountered in tobacco smoke and high‐temperature cooked meat—and therapeutic agents. Population studies have documented marked ethnic and geographic variability in NAT2 allele frequencies, and structural investigations have elucidated key features underlying its substrate specificity and genetic diversity. These findings underscore the evolutionary pressures acting on NAT2 and establish its importance in interindividual variability in xenobiotic metabolism."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "4"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nNAT2 is central to the metabolism of several clinically important drugs. In the context of antituberculosis therapy, NAT2 acetylates isoniazid—the drug primarily implicated in drug‐induced hepatotoxicity. Multiple studies have shown that individuals with slow acetylator genotypes accumulate hepatotoxic intermediates, thereby increasing their risk for antituberculosis drug–induced liver injury. Similar genotype–phenotype associations have been observed with other medications, as NAT2 genotype has been used to predict isoniazid clearance and to guide personalized dosing strategies for drugs such as sulfasalazine. These observations establish NAT2 as a critical determinant in drug disposition and toxicity."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "5", "end_ref": "11"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nBeyond drug metabolism, NAT2 modulates the bioactivation of potential carcinogens, thereby influencing cancer susceptibility in gene–environment interaction contexts. Studies in bladder cancer, for example, have documented that slow acetylators are at greater risk when exposed to tobacco‐derived arylamines and occupational carcinogens, whereas interactions with other metabolizing enzymes further modify risk. Similar relationships have been reported in colorectal cancer, where NAT2 polymorphisms—often in concert with variations in NAT1 or CYP1A2—appear to modulate the carcinogenic effects of heterocyclic amines from well‐done meat. Additional investigations have highlighted associations between NAT2 acetylator status and risks for laryngeal, orofacial, breast, and even gastric or esophageal cancers, with smoking and dietary exposures frequently acting as strong modifiers. Collectively, these findings support a functional role for NAT2 in determining individual susceptibility to cancer through its effects on carcinogen metabolism."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "12", "end_ref": "31"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nEmerging studies continue to expand the clinical and biological implications of NAT2 variation. Recent work has linked a nonsynonymous NAT2 variant not only to altered enzymatic activity but also to differences in insulin sensitivity, thereby broadening the enzyme’s impact to metabolic regulation. Moreover, further population‐based investigations into drug‐induced liver injury emphasize the promise of NAT2 genotyping as a tool for personalized medicine. These additional perspectives highlight the diverse roles of NAT2 in both pharmacokinetics and disease susceptibility, reaffirming its status as a key mediator at the interface of environmental exposures and human health."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "32", "end_ref": "34"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "S Garte, L Gaspari, A K Alexandrie, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Metabolic gene polymorphism frequencies in control populations."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2001)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11751440"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11751440"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Elena A Gaikovitch, Ingolf Cascorbi, Przemyslaw M Mrozikiewicz, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Clin Pharmacol (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00228-003-0606-2"}], "href": "https://doi.org/10.1007/s00228-003-0606-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12879168"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12879168"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Hong Wu, Ludmila Dombrovsky, Wolfram Tempel, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M704138200"}], "href": "https://doi.org/10.1074/jbc.M704138200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17656365"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17656365"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Samar I Hamdy, Masahiro Hiratsuka, Kaori Narahara, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Br J Clin Pharmacol (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1046/j.1365-2125.2003.01786.x"}], "href": "https://doi.org/10.1046/j.1365-2125.2003.01786.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12814450"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12814450"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hepatology (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1053/jhep.2002.32102"}], "href": "https://doi.org/10.1053/jhep.2002.32102"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11915035"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11915035"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hepatology (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1053/jhep.2003.50144"}], "href": "https://doi.org/10.1053/jhep.2003.50144"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12668988"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12668988"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "B Roy, A Chowdhury, S Kundu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Gastroenterol Hepatol (2001)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1046/j.1440-1746.2001.02585.x"}], "href": "https://doi.org/10.1046/j.1440-1746.2001.02585.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11595069"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11595069"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Martina Kinzig-Schippers, Dorota Tomalik-Scharte, Alexander Jetter, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?"}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Antimicrob Agents Chemother (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1128/AAC.49.5.1733-1738.2005"}], "href": "https://doi.org/10.1128/AAC.49.5.1733-1738.2005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15855489"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15855489"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Hyun-Jung Cho, Won-Jung Koh, Yon-Ju Ryu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Tuberculosis (Edinb) (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.tube.2007.05.012"}], "href": "https://doi.org/10.1016/j.tube.2007.05.012"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17950035"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17950035"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "L G Possuelo, J A Castelan, T C de Brito, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Clin Pharmacol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00228-008-0484-8"}], "href": "https://doi.org/10.1007/s00228-008-0484-8"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18421452"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18421452"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Raquel Lima de Figueiredo Teixeira, Renata Gomes Morato, Pedro Hernan Cabello, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mem Inst Oswaldo Cruz (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1590/s0074-02762011000600011"}], "href": "https://doi.org/10.1590/s0074-02762011000600011"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22012226"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22012226"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Montserrat García-Closas, Núria Malats, Debra Silverman, et al. "}, {"type": "b", "children": [{"type": "t", "text": "NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Lancet (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/S0140-6736(05)67137-1"}], "href": "https://doi.org/10.1016/S0140-6736(05"}, {"type": "t", "text": "67137-1) PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16112301"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16112301"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Nathaniel Rothman, Montserrat Garcia-Closas, Nilanjan Chatterjee, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.687"}], "href": "https://doi.org/10.1038/ng.687"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20972438"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20972438"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Rayjean J Hung, Paolo Boffetta, Paul Brennan, et al. "}, {"type": "b", "children": [{"type": "t", "text": "GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Cancer (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/ijc.20157"}], "href": "https://doi.org/10.1002/ijc.20157"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15122594"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15122594"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "L Le Marchand, J H Hankin, L R Wilkens, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2001)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11751443"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11751443"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Carmen Lilla, Emaculate Verla-Tebit, Angela Risch, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1055-9965.EPI-05-0618"}], "href": "https://doi.org/10.1158/1055-9965.EPI-05-0618"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16434594"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16434594"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "P Vineis, D Marinelli, H Autrup, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2001)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11751441"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11751441"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "L E Moore, D R Baris, J D Figueroa, et al. "}, {"type": "b", "children": [{"type": "t", "text": "GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgq223"}], "href": "https://doi.org/10.1093/carcin/bgq223"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21037224"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21037224"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "Manuela Gago-Dominguez, Douglas A Bell, Mary A Watson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/24.3.483"}], "href": "https://doi.org/10.1093/carcin/24.3.483"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12663508"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12663508"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Marzena Gajecka, Malgorzata Rydzanicz, Renata Jaskula-Sztul, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mutat Res (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.mrfmmm.2005.01.027"}], "href": "https://doi.org/10.1016/j.mrfmmm.2005.01.027"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15914211"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15914211"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "Min Shi, Kaare Christensen, Clarice R Weinberg, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Hum Genet (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1086/510518"}], "href": "https://doi.org/10.1086/510518"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17160896"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17160896"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Christine B Ambrosone, Silke Kropp, Jun Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1055-9965.EPI-07-0598"}], "href": "https://doi.org/10.1158/1055-9965.EPI-07-0598"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18187392"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18187392"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Michelle Cotterchio, Beatrice A Boucher, Michael Manno, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1055-9965.EPI-08-0341"}], "href": "https://doi.org/10.1158/1055-9965.EPI-08-0341"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18990750"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18990750"}]}, {"type": "r", "ref": 24, "children": [{"type": "t", "text": "A C Deitz, W Zheng, M A Leff, et al. "}, {"type": "b", "children": [{"type": "t", "text": "N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2000)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11008907"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11008907"}]}, {"type": "r", "ref": 25, "children": [{"type": "t", "text": "Balram Chowbay, Shufeng Zhou, Edmund J D Lee "}, {"type": "b", "children": [{"type": "t", "text": "An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Drug Metab Rev (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1081/dmr-28805"}], "href": "https://doi.org/10.1081/dmr-28805"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15931768"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15931768"}]}, {"type": "r", "ref": 26, "children": [{"type": "t", "text": "Jian Gu, Dong Liang, Yunfei Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mutat Res (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.mrgentox.2004.11.012"}], "href": "https://doi.org/10.1016/j.mrgentox.2004.11.012"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15725609"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15725609"}]}, {"type": "r", "ref": 27, "children": [{"type": "t", "text": "Mariana C Stern, Laura R Johnson, Douglas A Bell, et al. "}, {"type": "b", "children": [{"type": "t", "text": "XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2002)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12376500"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12376500"}]}, {"type": "r", "ref": 28, "children": [{"type": "t", "text": "Yu Zang, Mark A Doll, Shuang Zhao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgm085"}], "href": "https://doi.org/10.1093/carcin/bgm085"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17434923"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17434923"}]}, {"type": "r", "ref": 29, "children": [{"type": "t", "text": "Stefania Boccia, Fakhredin A Sayed-Tabatabaei, Roberto Persiani, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "BMC Cancer (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/1471-2407-7-206"}], "href": "https://doi.org/10.1186/1471-2407-7-206"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17996038"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17996038"}]}, {"type": "r", "ref": 30, "children": [{"type": "t", "text": "Federica Gemignani, Stefano Landi, Neonilia Szeszenia-Dabrowska, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgm021"}], "href": "https://doi.org/10.1093/carcin/bgm021"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17259654"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17259654"}]}, {"type": "r", "ref": 31, "children": [{"type": "t", "text": "J H Barrett, G Smith, R Waxman, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/24.2.275"}], "href": "https://doi.org/10.1093/carcin/24.2.275"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12584178"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12584178"}]}, {"type": "r", "ref": 32, "children": [{"type": "t", "text": "Joshua W Knowles, Weijia Xie, Zhongyang Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Clin Invest (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1172/JCI74692"}], "href": "https://doi.org/10.1172/JCI74692"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25798622"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25798622"}]}, {"type": "r", "ref": 33, "children": [{"type": "t", "text": "F Sun, Y Chen, Y Xiang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Tuberc Lung Dis (2008)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18713495"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18713495"}]}, {"type": "r", "ref": 34, "children": [{"type": "t", "text": "S-W Lee, L S-C Chung, H-H Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Tuberc Lung Dis (2010)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20392357"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20392357"}]}]}]}
|
| Synonyms | PNAT, AAC2, NAT-2 |
| Proteins | ARY2_HUMAN |
| NCBI Gene ID | 10 |
| API | |
| Download Associations | |
| Predicted Functions |
![]() |
| Co-expressed Genes |
![]() |
| Expression in Tissues and Cell Lines |
![]() |
NAT2 has 4,287 functional associations with biological entities spanning 8 categories (molecular profile, organism, chemical, functional term, phrase or reference, disease, phenotype or trait, structural feature, cell line, cell type or tissue, gene, protein or microRNA) extracted from 87 datasets.
Click the + buttons to view associations for NAT2 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles | tissues with high or low expression of NAT2 gene relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset. | |
| Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray | tissue samples with high or low expression of NAT2 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray dataset. | |
| Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles | tissues with high or low expression of NAT2 gene relative to other tissues from the Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles dataset. | |
| BioGPS Cell Line Gene Expression Profiles | cell lines with high or low expression of NAT2 gene relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset. | |
| BioGPS Human Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of NAT2 gene relative to other cell types and tissues from the BioGPS Human Cell Type and Tissue Gene Expression Profiles dataset. | |
| BioGPS Mouse Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of NAT2 gene relative to other cell types and tissues from the BioGPS Mouse Cell Type and Tissue Gene Expression Profiles dataset. | |
| CCLE Cell Line Gene CNV Profiles | cell lines with high or low copy number of NAT2 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset. | |
| CCLE Cell Line Gene Expression Profiles | cell lines with high or low expression of NAT2 gene relative to other cell lines from the CCLE Cell Line Gene Expression Profiles dataset. | |
| CellMarker Gene-Cell Type Associations | cell types associated with NAT2 gene from the CellMarker Gene-Cell Type Associations dataset. | |
| ChEA Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of NAT2 gene from the CHEA Transcription Factor Binding Site Profiles dataset. | |
| ChEA Transcription Factor Targets | transcription factors binding the promoter of NAT2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset. | |
| ChEA Transcription Factor Targets 2022 | transcription factors binding the promoter of NAT2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset. | |
| CMAP Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of NAT2 gene from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| COMPARTMENTS Curated Protein Localization Evidence Scores | cellular components containing NAT2 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores | cellular components co-occuring with NAT2 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset. | |
| COSMIC Cell Line Gene CNV Profiles | cell lines with high or low copy number of NAT2 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset. | |
| COSMIC Cell Line Gene Mutation Profiles | cell lines with NAT2 gene mutations from the COSMIC Cell Line Gene Mutation Profiles dataset. | |
| CTD Gene-Chemical Interactions | chemicals interacting with NAT2 gene/protein from the curated CTD Gene-Chemical Interactions dataset. | |
| CTD Gene-Disease Associations | diseases associated with NAT2 gene/protein from the curated CTD Gene-Disease Associations dataset. | |
| DepMap CRISPR Gene Dependency | cell lines with fitness changed by NAT2 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset. | |
| DISEASES Curated Gene-Disease Association Evidence Scores 2025 | diseases involving NAT2 gene from the DISEASES Curated Gene-Disease Association Evidence Scores 2025 dataset. | |
| DISEASES Experimental Gene-Disease Association Evidence Scores | diseases associated with NAT2 gene in GWAS datasets from the DISEASES Experimental Gene-Disease Assocation Evidence Scores dataset. | |
| DISEASES Experimental Gene-Disease Association Evidence Scores 2025 | diseases associated with NAT2 gene in GWAS datasets from the DISEASES Experimental Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores | diseases co-occuring with NAT2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores 2025 | diseases co-occuring with NAT2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DisGeNET Gene-Disease Associations | diseases associated with NAT2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset. | |
| DisGeNET Gene-Phenotype Associations | phenotypes associated with NAT2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Phenoptype Associations dataset. | |
| DrugBank Drug Targets | interacting drugs for NAT2 protein from the curated DrugBank Drug Targets dataset. | |
| ENCODE Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at NAT2 gene from the ENCODE Histone Modification Site Profiles dataset. | |
| ENCODE Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of NAT2 gene from the ENCODE Transcription Factor Binding Site Profiles dataset. | |
| ENCODE Transcription Factor Targets | transcription factors binding the promoter of NAT2 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset. | |
| ESCAPE Omics Signatures of Genes and Proteins for Stem Cells | PubMedIDs of publications reporting gene signatures containing NAT2 from the ESCAPE Omics Signatures of Genes and Proteins for Stem Cells dataset. | |
| GAD Gene-Disease Associations | diseases associated with NAT2 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset. | |
| GAD High Level Gene-Disease Associations | diseases associated with NAT2 gene in GWAS and other genetic association datasets from the GAD High Level Gene-Disease Associations dataset. | |
| GDSC Cell Line Gene Expression Profiles | cell lines with high or low expression of NAT2 gene relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset. | |
| GeneRIF Biological Term Annotations | biological terms co-occuring with NAT2 gene in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset. | |
| GeneSigDB Published Gene Signatures | PubMedIDs of publications reporting gene signatures containing NAT2 from the GeneSigDB Published Gene Signatures dataset. | |
| GEO Signatures of Differentially Expressed Genes for Diseases | disease perturbations changing expression of NAT2 gene from the GEO Signatures of Differentially Expressed Genes for Diseases dataset. | |
| GEO Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of NAT2 gene from the GEO Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of NAT2 gene from the GEO Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations | transcription factor perturbations changing expression of NAT2 gene from the GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Viral Infections | virus perturbations changing expression of NAT2 gene from the GEO Signatures of Differentially Expressed Genes for Viral Infections dataset. | |
| GO Biological Process Annotations 2015 | biological processes involving NAT2 gene from the curated GO Biological Process Annotations 2015 dataset. | |
| GO Cellular Component Annotations 2015 | cellular components containing NAT2 protein from the curated GO Cellular Component Annotations 2015 dataset. | |
| GO Molecular Function Annotations 2015 | molecular functions performed by NAT2 gene from the curated GO Molecular Function Annotations 2015 dataset. | |
| GO Molecular Function Annotations 2023 | molecular functions performed by NAT2 gene from the curated GO Molecular Function Annotations 2023 dataset. | |
| GTEx Tissue Gene Expression Profiles | tissues with high or low expression of NAT2 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles dataset. | |
| GTEx Tissue Gene Expression Profiles 2023 | tissues with high or low expression of NAT2 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles 2023 dataset. | |
| GTEx Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of NAT2 gene relative to other tissue samples from the GTEx Tissue Sample Gene Expression Profiles dataset. | |
| GWASdb SNP-Disease Associations | diseases associated with NAT2 gene in GWAS and other genetic association datasets from the GWASdb SNP-Disease Associations dataset. | |
| GWASdb SNP-Phenotype Associations | phenotypes associated with NAT2 gene in GWAS datasets from the GWASdb SNP-Phenotype Associations dataset. | |
| Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles | cell lines with high or low expression of NAT2 gene relative to other cell lines from the Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles dataset. | |
| HMDB Metabolites of Enzymes | interacting metabolites for NAT2 protein from the curated HMDB Metabolites of Enzymes dataset. | |
| HPA Tissue Gene Expression Profiles | tissues with high or low expression of NAT2 gene relative to other tissues from the HPA Tissue Gene Expression Profiles dataset. | |
| HPA Tissue Protein Expression Profiles | tissues with high or low expression of NAT2 protein relative to other tissues from the HPA Tissue Protein Expression Profiles dataset. | |
| HPA Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of NAT2 gene relative to other tissue samples from the HPA Tissue Sample Gene Expression Profiles dataset. | |
| HuGE Navigator Gene-Phenotype Associations | phenotypes associated with NAT2 gene by text-mining GWAS publications from the HuGE Navigator Gene-Phenotype Associations dataset. | |
| InterPro Predicted Protein Domain Annotations | protein domains predicted for NAT2 protein from the InterPro Predicted Protein Domain Annotations dataset. | |
| JASPAR Predicted Transcription Factor Targets | transcription factors regulating expression of NAT2 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset. | |
| KEGG Pathways | pathways involving NAT2 protein from the KEGG Pathways dataset. | |
| Kinase Library Tyrosine Kinome Atlas | kinases that phosphorylate NAT2 protein from the Kinase Library Tyrosine Kinome Atlas dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles | cell lines with high or low copy number of NAT2 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset. | |
| KnockTF Gene Expression Profiles with Transcription Factor Perturbations | transcription factor perturbations changing expression of NAT2 gene from the KnockTF Gene Expression Profiles with Transcription Factor Perturbations dataset. | |
| LINCS L1000 CMAP Chemical Perturbation Consensus Signatures | small molecule perturbations changing expression of NAT2 gene from the LINCS L1000 CMAP Chemical Perturbations Consensus Signatures dataset. | |
| LINCS L1000 CMAP CRISPR Knockout Consensus Signatures | gene perturbations changing expression of NAT2 gene from the LINCS L1000 CMAP CRISPR Knockout Consensus Signatures dataset. | |
| LOCATE Curated Protein Localization Annotations | cellular components containing NAT2 protein in low- or high-throughput protein localization assays from the LOCATE Curated Protein Localization Annotations dataset. | |
| LOCATE Predicted Protein Localization Annotations | cellular components predicted to contain NAT2 protein from the LOCATE Predicted Protein Localization Annotations dataset. | |
| MGI Mouse Phenotype Associations 2023 | phenotypes of transgenic mice caused by NAT2 gene mutations from the MGI Mouse Phenotype Associations 2023 dataset. | |
| MotifMap Predicted Transcription Factor Targets | transcription factors regulating expression of NAT2 gene predicted using known transcription factor binding site motifs from the MotifMap Predicted Transcription Factor Targets dataset. | |
| MoTrPAC Rat Endurance Exercise Training | tissue samples with high or low expression of NAT2 gene relative to other tissue samples from the MoTrPAC Rat Endurance Exercise Training dataset. | |
| MPO Gene-Phenotype Associations | phenotypes of transgenic mice caused by NAT2 gene mutations from the MPO Gene-Phenotype Associations dataset. | |
| MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations | gene perturbations changing expression of NAT2 gene from the MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations dataset. | |
| MW Enzyme Metabolite Associations | interacting metabolites for NAT2 protein from the MW Gene Metabolite Associations dataset. | |
| OMIM Gene-Disease Associations | phenotypes associated with NAT2 gene from the curated OMIM Gene-Disease Associations dataset. | |
| Pathway Commons Protein-Protein Interactions | interacting proteins for NAT2 from the Pathway Commons Protein-Protein Interactions dataset. | |
| PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of NAT2 gene from the PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| PFOCR Pathway Figure Associations 2023 | pathways involving NAT2 protein from the PFOCR Pathway Figure Associations 2023 dataset. | |
| PFOCR Pathway Figure Associations 2024 | pathways involving NAT2 protein from the Wikipathways PFOCR 2024 dataset. | |
| Reactome Pathways 2014 | pathways involving NAT2 protein from the Reactome Pathways dataset. | |
| Reactome Pathways 2024 | pathways involving NAT2 protein from the Reactome Pathways 2024 dataset. | |
| Roadmap Epigenomics Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at NAT2 gene from the Roadmap Epigenomics Histone Modification Site Profiles dataset. | |
| TargetScan Predicted Nonconserved microRNA Targets | microRNAs regulating expression of NAT2 gene predicted using nonconserved miRNA seed sequences from the TargetScan Predicted Nonconserved microRNA Targets dataset. | |
| TCGA Signatures of Differentially Expressed Genes for Tumors | tissue samples with high or low expression of NAT2 gene relative to other tissue samples from the TCGA Signatures of Differentially Expressed Genes for Tumors dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores | tissues with high expression of NAT2 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores | tissues co-occuring with NAT2 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset. | |
| WikiPathways Pathways 2014 | pathways involving NAT2 protein from the Wikipathways Pathways 2014 dataset. | |
| WikiPathways Pathways 2024 | pathways involving NAT2 protein from the WikiPathways Pathways 2024 dataset. | |